STOCKHOLM, Nov. 21, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Pia Baumann has been recruited as its new Chief Medical Officer (CMO). Her role includes overall responsibility for the continued clinical development of the candidate drug fostroxacitabine bralpamide (fostrox). She will be part of the company's management team and will take up her position on February 20, 2023.
Read more at prnewswire.comMedivir recruits Pia Baumann as new Chief Medical Officer
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
